文献速递骨质疏松与钙磷/甲状旁腺

血清25-羟维生素D不足与骨病关系的探索

Serum 25-Hydroxyvitamin D Insufficiency in Search of a Bone Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

研究在11855名参与者中检测25(OH)D、钙、磷、PTH等,并在150人中测骨密度与微结构。发现钙、PTH、碱性磷酸酶拐点在25(OH)D<30 nmol/L,30-75 nmol/L无异常,挑战该范围补充维生素D的依据。

要点

  • 25(OH)D<30 nmol/L时钙、PTH、碱性磷酸酶出现拐点,提示缺乏状态。
  • 25(OH)D在30-75 nmol/L者无骨密度、微结构或矿化异常。
  • 该结果挑战对25(OH)D 30-75 nmol/L人群补充维生素D的依据。

核心结论

  • 25(OH)D≤30 nmol/L时生化异常支持缺乏状态易致骨病,但30-75 nmol/L不足者无有害效应,挑战补充维生素D的依据。

研究设计与样本

  • 在11855名参与者中测量25(OH)D、钙、磷、肌酐和PTH,并在150名子集中测量1型胶原C端端肽、1型前胶原N端前肽、面积骨密度、桡骨远端微结构和基质矿化密度。

主要发现

  • 钙、PTH和碱性磷酸酶的拐点出现在25(OH)D<30 nmol/L阈值,超过75 nmol/L无平台期。
  • 在测骨形态的子集中,血清25(OH)D浓度与面积骨密度、骨小梁密度、皮质孔隙率或基质矿化密度之间未检测到关联。
  • 1439名25(OH)D<30 nmol/L参与者中,6.1%血钙低、3.4%血磷低、6.1%碱性磷酸酶高、34.2%PTH升高,多数无任何异常。

关键数值与推荐

  • 25(OH)D不足定义为<75 nmol/L,缺乏定义为<30 nmol/L。
  • 钙、PTH和碱性磷酸酶的拐点阈值为25(OH)D<30 nmol/L。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Vitamin D "insufficiency" and "deficiency" are defined as serum 25-hydroxyvitamin D [25(OH)D] levels <75 and <30 nmol/L, respectively. We aimed to determine whether these values signal hypocalcemia and hypophosphatemia, secondary hyperparathyroidism, high bone remodeling, low areal bone mineral density (aBMD), microstructural deterioration, or reduced matrix mineralization density (MMD) and so suggest whether bone fragility is present. METHODS: Concentrations of 25(OH)D, calcium, phosphate, creatinine, and parathyroid hormone (PTH) were measured in 11,855 participants. Serum C-terminal telopeptide of type 1 collagen, procollagen type 1 N-terminal propeptide (P1NP), aBMD, and distal radius microstructure and MMD were measured in a second subset of 150 participants. RESULTS: A breakpoint for calcium, PTH, and alkaline phosphatase was identified at a threshold 25(OH)D level <30 nmol/L. There was no plateau beyond 75 nmol/L. In the subgroup with measurements of bone morphology, no associations were detectable between serum 25(OH)D concentration, aBMD, trabecular density, cortical porosity, or MMD. Among 1439 participants with serum 25(OH)D <30 nmol/L, 6.1% had low serum calcium, 3.4% had low serum phosphate, 6.1% had high alkaline phosphatase, and 34.2% had elevated PTH. Most participants did not have any abnormalities. CONCLUSION: At a 25(OH)D threshold of ≤30 nmol/L, abnormalities in biochemical features support the notion of a "deficiency" state predisposing to bone disease. However, no deleterious effects were found in participants within an insufficiency threshold of a 25(OH)D level of 30 to 75 nmol/L, which challenges the rationale justifying vitamin D supplementation in these individuals.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Shah S, Chiang C, Sikaris K, et al. Serum 25-Hydroxyvitamin D Insufficiency in Search of a Bone Disease. J Clin Endocrinol Metab. 2017. PMID: 28379394. doi:10.1210/jc.2016-3189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。